financetom
Business
financetom
/
Business
/
Archer-Daniels-Midland Stock Dips After Q3 Preliminary Results: Earnings Miss, Guidance Cut Amid Restatements
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Archer-Daniels-Midland Stock Dips After Q3 Preliminary Results: Earnings Miss, Guidance Cut Amid Restatements
Nov 5, 2024 7:00 AM

Archer-Daniels-Midland Company ( ADM ) shares are trading lower on Tuesday.

Yesterday, the company reported third-quarter preliminary adjusted earnings per share of $1.09, compared with street view of $1.25.

The company will restate previously filed fiscal year 2023 Form 10-K and subsequent Forms 10-Q. The company said it has decided to postpone the webcast originally scheduled for November 5 at 9 a.m. Central Time.

The restated filings will include corrections for newly identified errors related to intersegment sales, will reflect the previously-corrected errors, and will provide disclosures applicable to restated segment information.

“Our third quarter operating results were mixed in a challenging quarter for the business,” said Chair of the Board and CEO Juan Luciano.

Archer-Daniels-Midland ( ADM ) said net earnings are expected to be $18 million, with adjusted net earnings forecasted at $530 million. The company also anticipates a $461 million non-cash charge against GAAP earnings for the third quarter related to its Wilmar equity investment.

“We are taking the necessary actions to improve performance and drive continued value creation,” Luciano added.

Also Read: Boeing Workers End Seven-Week Strike By Accepting New Contract With Major Pay Increases

Ag Services and Oilseeds (AS&O) segment operating profit was $480 million during the third quarter of 2024, down 43% compared to the prior-year quarter. Carbohydrate Solutions segment operating profit was $452 million for the third quarter of 2024, down 3% compared to the prior year period. Nutrition segment operating profit was $105 million for the third quarter of 2024, down 19% compared to the prior year period.

“While Carbohydrate Solutions achieved strong results, our Ag Services and Oilseeds and Nutrition businesses delivered results below expectations, impacted by softer than expected market conditions and the pace of our planned improvement efforts,” added Luciano.

Outlook: The company has lowered its 2024 adjusted EPS guidance to a range of $4.50 – $5.00, down from the previous range of $5.25 – $6.25, and below the $5.23 analyst estimate.

The company’s revised outlook reflects trends in ADM’s performance to date, legislative and regulatory policy uncertainties, and ongoing headwinds from slower market demand and internal operational challenges.

Price Action: ADM shares are trading lower by 9.3% to $50.16 at last check Tuesday.

Read Next:

Palantir’s AI Gamble Pays Off As Customer Revenue From Single Customer Jumps 12x In Under 8 Months — Alex Karp Quips: ‘We Should Just Go Home’

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Premium Catering Board Authorizes $1 Million Share Repurchase Program
Premium Catering Board Authorizes $1 Million Share Repurchase Program
Jun 26, 2025
11:57 AM EDT, 06/26/2025 (MT Newswires) -- Premium Catering ( PC ) said Thursday its board has authorized the repurchase of up to $1 million common shares from time to time. This repurchase authorization underscores the board and management's belief that at times our share price may be undervalued relative to our long-term opportunity, stated Yu Chun Yin, executive director...
Lisata Reports Survival, Response Benefits With Certepetide in Pancreatic Cancer Trial
Lisata Reports Survival, Response Benefits With Certepetide in Pancreatic Cancer Trial
Jun 26, 2025
11:58 AM EDT, 06/26/2025 (MT Newswires) -- Lisata Therapeutics ( LSTA ) , the Australasian Gastro-Intestinal Trials Group, and the University of Sydney's NHMRC Clinical Trials Centre said Thursday that preliminary data from Cohort B of a phase 2b trial showed higher progression-free survival and response rates in metastatic pancreatic cancer patients treated with certepetide and chemotherapy compared with placebo....
Equinor, Shell Name Joint Venture Adura
Equinor, Shell Name Joint Venture Adura
Jun 26, 2025
11:58 AM EDT, 06/26/2025 (MT Newswires) -- Equinor ( EQNR ) and Shell (SHEL) said Thursday that their joint venture combining their UK offshore oil and gas assets and operations will be named Adura. The joint venture, first announced in December 2024, is anticipated to launch by year-end, pending regulatory approvals, the companies said. It will be based in Silver...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved